The benefit of double lung transplant (DLT) over single lung transplant (SLT) in idiopathic pulmonary fibrosis (IPF) remains controversial. The purpose of this study is to determine if there is a survival benefit for DLT versus SLT in recipients concurrently listed for DLT and SLT.The United Network for Organ Sharing provided de-identified patient-level data. The study population included 1,002 lung transplant recipients concurrently listed for DLT and SLT, aged ≥18yo, and transplanted 1/1/01-12/31/09. Kaplan-meier curves and log-rank test were used to assess the relationship between DLT and actuarial survival. Cox multivariate regression analysis was used to assess the effect of multiple variables (including recipient age, donor age, ischemic time, BMI, cardiac index <2, recipient sex, and donor sex) on survival following lung transplant. The primary outcomes measure was actuarial post-transplant survival expressed in years.Among the study population, 434 (43.31%) recipients underwent SLT and 568 (56.69%) recipients underwent DLT. This analysis includes 2725.6 years at risk and median survival was 5.31 years. In univariate (p=0.192) and multivariate (p=0.979) regression analysis there was no difference in survival between DLT and SLT. [figure 1]Among IPF recipients concurrently listed for DLT and SLT, there is no statistical difference in actuarial survival between recipients undergoing DLT versus SLT. This analysis suggests that increased use of SLT in this population may increase the availability of organs to other candidates without comprising outcomes.